Loading the company…
Loading the company…
In the last ten years FDA made 1 decision for Orthofundamentals (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2022 (1). The latest was on 2022-04-11.
| Family | Decisions on record |
|---|---|
| SI joint fusion | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2022-04-11 | 510(k) | K212962 | TRELLIS SI Joint Fusion System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Orthofundamentals.
In 2025, Orthofundamentals reported engagement with 18 surgeons and other clinicians in the states MedaRep covers, worth $13K in consulting, speaking, meals and travel for its device products, the most in Georgia ($6,250 to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Georgia ($6,250, 1 engaged), Virginia ($2,761, 1 engaged), California ($1,500, 1 engaged), Texas ($1,351, 4 engaged), District of Columbia ($500, 1 engaged).